FDA Advisory Panel Recommends Approval of Pfizer-BioNTech Vaccine
Pfizer Inc (NYSE:PFE)r shares jumped 2% in after-hours trading after an advisory panel to the U.S. Food and Drug Administration recommended approval of the pharma's Covid-19 vaccine for emergency use.
The recommendation isn't binding, but it clears the way for the FDA to approve the drug and get vaccinations underway for millions of Americans, after the U.K. and Canada regulators cleared the vaccine. FDA approval could come as early as Friday.
Pfizer developed the vaccine with BioNTech SE (NASDAQ:BNTX). In trials, it proved to be 95% effective, though it requires storage in extremely cold environments and may not be suitable for those with severe allergies. Another vaccine developed by Moderna Inc (NASDAQ:MRNA) is still awaiting emergency authorization.
The good news comes as Covid-19 cases spike in the U.S., recording daily records for new infections and deaths.
Reference by: investing.com
Dec 11, 2020
2022-01-14 16:05Portal to Unfold the Largest Total Addressable Machine (TAM) for DeFi
2022-01-10 08:23Australia COVID-19 infections hit 1 million as Omicron drives record surge
2021-12-14 10:37U.S. House panel details case against former top Trump aide Meadows